Aveanna Healthcare (NASDAQ:AVAH) Shares Gap Down Following Analyst Downgrade

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)’s share price gapped down prior to trading on Friday after BMO Capital Markets lowered their price target on the stock from $11.00 to $10.00. The stock had previously closed at $6.34, but opened at $6.03. BMO Capital Markets currently has an outperform rating on the stock. Aveanna Healthcare shares last traded at $6.44, with a volume of 496,743 shares trading hands.

A number of other research analysts have also commented on the stock. Truist Financial reduced their price target on shares of Aveanna Healthcare from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Friday. Zacks Research downgraded Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. UBS Group boosted their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Barclays upped their target price on Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Finally, Raymond James Financial upgraded Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target for the company in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.81.

Insider Activity at Aveanna Healthcare

In other news, CEO Jeff Shaner sold 173,225 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25. Following the completion of the sale, the chief executive officer directly owned 2,650,892 shares in the company, valued at approximately $19,112,931.32. The trade was a 6.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Edwin C. Reisz sold 60,769 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $438,144.49. Following the completion of the sale, the insider directly owned 1,447,057 shares of the company’s stock, valued at $10,433,280.97. This trade represents a 4.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 998,595 shares of company stock valued at $7,567,770 over the last 90 days. 7.80% of the stock is owned by insiders.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results beat consensus — revenue grew strongly year‑over‑year and the company topped EPS and revenue estimates, providing fundamental support for the stock. Press Release
• Positive Sentiment: Raymond James upgraded AVAH to “strong-buy” and set a $13 price target, which is a bullish catalyst and likely helping intraday buying interest. Finviz item
• Neutral Sentiment: BMO trimmed its price target from $11 to $10 but maintained an “outperform” rating — a modest pullback in upside but not a negative rating change. Benzinga
• Neutral Sentiment: Aveanna issued 2026 guidance and a growth outlook; the details are being parsed by investors and helped explain the mixed market reaction (earnings beat vs. cautious forward commentary). TipRanks
• Neutral Sentiment: Reported short‑interest entries show anomalous “0 shares”/NaN data for March (data likely erroneous), so short‑interest signals are not meaningful right now.
• Negative Sentiment: Truist lowered its price target to $9 and moved to a “hold” rating, reducing analyst support and putting downside pressure on the stock. Benzinga
• Negative Sentiment: Market headlines flagged that Aveanna’s revenue outlook/trend in guidance trailed some consensus expectations, which prompted a pullback in some coverage and weighed on sentiment. MSN

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AVAH. Caitong International Asset Management Co. Ltd boosted its holdings in Aveanna Healthcare by 252.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after acquiring an additional 2,400 shares during the period. Invesco Ltd. increased its stake in Aveanna Healthcare by 1,001.5% in the 4th quarter. Invesco Ltd. now owns 360,464 shares of the company’s stock worth $2,945,000 after purchasing an additional 327,738 shares during the period. Mackenzie Financial Corp lifted its position in Aveanna Healthcare by 12.7% in the fourth quarter. Mackenzie Financial Corp now owns 216,200 shares of the company’s stock valued at $1,810,000 after purchasing an additional 24,447 shares during the last quarter. Zimmer Partners LP purchased a new stake in shares of Aveanna Healthcare during the fourth quarter valued at approximately $6,189,000. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Aveanna Healthcare during the fourth quarter valued at approximately $1,915,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Price Performance

The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. The firm’s fifty day moving average price is $7.84 and its 200-day moving average price is $8.49. The stock has a market cap of $1.36 billion, a P/E ratio of 6.39 and a beta of 2.07.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.